tradingkey.logo

AtriCure Inc

ATRC
查看詳細走勢圖
40.330USD
-0.220-0.54%
收盤 12/26, 16:00美東報價延遲15分鐘
2.00B總市值
虧損本益比TTM

AtriCure Inc

40.330
-0.220-0.54%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.54%

5天

-1.51%

1月

+11.93%

6月

+22.66%

今年開始到現在

+31.97%

1年

+31.15%

查看詳細走勢圖

TradingKey AtriCure Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

AtriCure Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名12/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價51.67。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

AtriCure Inc評分

相關信息

行業排名
12 / 207
全市場排名
74 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 9 分析師
買入
評級
51.667
目標均價
+32.68%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

AtriCure Inc亮點

亮點風險
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
業績高增長
公司營業收入穩步增長,連續3年增長40.84%
估值低估
公司最新PE估值-66.36,處於3年歷史低位
機構減倉
最新機構持股49.59M股,環比減少0.21%
HACAX持倉
明星投資者HACAX持倉,最新持倉28.64K股

AtriCure Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

AtriCure Inc簡介

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
公司代碼ATRC
公司AtriCure Inc
CEOCarrel (Michael H)
網址https://www.atricure.com

常見問題

AtriCure Inc(ATRC)的當前股價是多少?

AtriCure Inc(ATRC)的當前股價是 40.330。

AtriCure Inc 的股票代碼是什麼?

AtriCure Inc的股票代碼是ATRC。

AtriCure Inc股票的52週最高點是多少?

AtriCure Inc股票的52週最高點是43.110。

AtriCure Inc股票的52週最低點是多少?

AtriCure Inc股票的52週最低點是28.290。

AtriCure Inc的市值是多少?

AtriCure Inc的市值是2.00B。

AtriCure Inc的淨利潤是多少?

AtriCure Inc的淨利潤為-44.70M。

現在AtriCure Inc(ATRC)的股票是買入、持有還是賣出?

根據分析師評級,AtriCure Inc(ATRC)的總體評級為買入,目標價格為51.667。

AtriCure Inc(ATRC)股票的每股收益(EPS TTM)是多少

AtriCure Inc(ATRC)股票的每股收益(EPS TTM)是-0.608。
KeyAI